Alnylam Pharmaceuticals (NASDAQ:ALNY) Emerges as a Decent Value Stock
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Alnylam Pharmaceuticals To Present New Helios-B Clinical Data At American Heart Association Scientific Sessions 2026
Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $380
Should You Buy The Dip In Alnylam Stock?
Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $323
Alnylam (ALNY) Stock Drops As Q3 Earnings Clash With Sales Concerns
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease - Slideshow
Alnylam Pharmaceuticals' Fundamentals Remain Strong Despite Lower-End Guidance Expectations, UBS Says
What Just Happened To Alnylam Stock?
Alnylam Q3 Update Disappoints as TTR Revenue Trends Toward Low End, RBC Says
TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $240
Goldman Sachs Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $320
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.